205245-17-6

Usage

Uses

Used in Organic Synthesis:
2-Fluoro-5-Iodo-3-Picoline is used as a key component in the synthesis of various complex chemical substances. Its distinctive chemical behavior, resulting from the combination of fluorine and iodine atoms, makes it a valuable asset in the creation of new compounds.
Used in Pharmaceutical Production:
2-Fluoro-5-Iodo-3-Picoline is used as a precursor in the production of pharmaceuticals. Its role in organic synthesis allows for the development of new drug molecules, contributing to advancements in medicine and healthcare. 2-FLUORO-5-IODO-3-PICOLINE is primarily utilized in laboratory settings, where its unique properties can be harnessed to create novel pharmaceutical agents.

InChI:InChI=1/C6H5FIN/c1-4-2-5(8)3-9-6(4)7/h2-3H,1H3

Upstream product

• 540-80-7 tert.-butylnitrite 
• 186593-48-6 5-amino-2-fluoro-3-methylpyridine 
• 109-63-7 trifluoroborane diethyl ether 

Relevant academic research and scientific papers

TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of tan protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tan protein, such that tan protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tan. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tan protein. Diseases or disorders that result from aggregation or accumulation of tan protein are treated or prevented with compounds and compositions of the present disclosure.

TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.